Laboratory Medicine ›› 2020, Vol. 35 ›› Issue (8): 803-805.DOI: 10.3969/j.issn.1673-8640.2020.08.014
Previous Articles Next Articles
Received:2019-10-08
Online:2020-08-30
Published:2020-09-24
CLC Number:
. [J]. Laboratory Medicine, 2020, 35(8): 803-805.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2020.08.014
| [1] | YOUNG L S,RICKINSON A B. Epstein-Barr virus:40 years on[J]. Nat Rev Cance,2004,4(10):757-768. |
| [2] | 王春玮,蔡星垚,张世宽,等. 不同样本中EBV DNA检出率的差异[J]. 检验医学,2019,34(8):763-764. |
| [3] | 刘璐瑶,孙金峤,王晓川. EB病毒感染的免疫机制研究进展[J]. 中国循证儿科杂志,2017,12(3):219-232. |
| [4] | RUF S,WAGNER H J. Determining EBV load:current best practice and future requirements[J]. Expert Rev Clin Immunol,2013,9(2):139-151. |
| [5] | 秦娟,何雅军. 外周血血浆和白细胞EBV DNA检测的比较[J]. 临床医学工程,2011,18(8):1174-1176. |
| [6] | FAN H,NICHOLLS J,CHUA D,et al. Laboratory markers of tumor burden in nasopharyngeal carcinoma:a comparison of viral load and serologic tests for Epstein-Barr virus[J]. Int J Cancer,2004,112(6):1036-1041. |
| [7] | 朱耀武,王春玉,潘莹莹,等. EB病毒核酸及血清学检测在EB病毒相关疾病中的应用研究[J]. 中华检验医学杂志,2017,40(3):195-200. |
| [8] | 陆海英,魏秀琴,徐小元,等. EBV抗体与EBV DNA水平的影响因素及其相关性分析[J]. 临床肝胆病杂志,2015,31(5):766-770. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
